NASDAQ:AXGT is back at another area of support/resistance. Friday will be another day to keep in mind in light of the company's event. There will be additional data and program updates at its Parkinson’s disease R&D Day on Friday. Remember what was also said originally with this particular trial
“These data, showing over 20 points of improvement on the UPDRS Part III ‘OFF’ motor function score, as well as meaningful improvements in quality of life measures, underscores the potentially best-in-class profile of AXO-Lenti-PD gene therapy in Parkinson’s disease. The totality of data seen thus far reinforces my belief that AXO-Lenti-PD has the potential to transform the treatment of patients with Parkinson’s disease through one-time administration of gene therapy.” - Gavin Corcoran, M.D., Chief R&D Officer at Axovant.
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
“These data, showing over 20 points of improvement on the UPDRS Part III ‘OFF’ motor function score, as well as meaningful improvements in quality of life measures, underscores the potentially best-in-class profile of AXO-Lenti-PD gene therapy in Parkinson’s disease. The totality of data seen thus far reinforces my belief that AXO-Lenti-PD has the potential to transform the treatment of patients with Parkinson’s disease through one-time administration of gene therapy.” - Gavin Corcoran, M.D., Chief R&D Officer at Axovant.
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events